Skip to main content
GILD
NASDAQ Life Sciences

FDA Approves Gilead's First-Ever Chronic HDV Drug for U.S. Market

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$134.17
Mkt Cap
$166.581B
52W Low
$104.46
52W High
$157.29
52W Position info
28% above low
Off High info
15% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GILD sits 28% above its 52-week low of $104.46.

Summary

The FDA has granted accelerated approval to Gilead Sciences' Hepcludex (bulevirtide-gmod) for chronic Hepatitis Delta Virus (HDV), marking the first approved treatment for this condition in the U.S. This approval addresses a critical unmet medical need for an estimated 40,000 to 80,000 patients in the U.S. and adds a new revenue stream to Gilead's portfolio. The drug is already available in Europe. This positive regulatory news follows Gilead's recent significant M&A activity and a revised full-year outlook to a net loss due to substantial IPR&D charges.

At the time of this announcement, GILD was trading at $134.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.6B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

GILD - Latest Insights

GILD
Nov 06, 2026, 12:16 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $167.82
Real-time Price: $169.72 info
Change: +$1.91 (+1%) info
Market Cap: $210.609B info
GILD
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $174.57
Real-time Price: $169.72 info
Change: -$4.84 (-3%) info
Market Cap: $210.609B info
GILD
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $165.88
Real-time Price: $169.72 info
Change: +$3.84 (+2%) info
Market Cap: $210.609B info
GILD
Oct 29, 2026, 4:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $164.00
Real-time Price: $169.72 info
Change: +$5.72 (+3%) info
Market Cap: $210.609B info
GILD
Oct 22, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $157.19
Real-time Price: $169.72 info
Change: +$12.53 (+8%) info
Market Cap: $210.609B info